135908-45-1

Upstream product

• 444344-90-5 ethyl 4-[[(benzyloxy)carbonyl]amino]-bicyclo[2.2.2]octane-1-carboxylate 
• 72653-21-5 ethyl 1-acetyl-4-oxocyclohexane-1-carboxylate 
• 1207166-75-3 ethyl 4-(benzylamino)-2-oxobicyclo[2.2.2]octane-1-carboxylate 
• 1207166-77-5 ethyl 4-(benzylamino)-2-hydroxybicyclo[2.2.2]octane-1-carboxylate 
• 1207166-79-7 ethyl 4-(benzylamino)bicyclo[2.2.2]oct-2-ene-1-carboxylate 
• 64-17-5 ethanol 
• 13595-17-0 4-amino-bicyclo[2.2.2]octane-1-carboxylic acid 
• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 
• 72653-14-6 1,5-di-tert-butyl 3-ethyl 3-acetylpentane-1,3,5-tricarboxylate 
• 141-97-9 ethyl acetoacetate 
• 1135619-58-7 1,5-di-tert-butyl 3-ethyl 3-acetylpentane-1,3,5-tricarboxylate 
• 1207166-78-6 ethyl 4-(benzylamino)-2-((methylsulfonyl)oxy)bicyclo[2.2.2]octane-1-carboxylate 

Downstream Products

• 105176-66-7 (4-aminobicyclo[2.2.2]octan-1-yl)methanol 

Relevant academic research and scientific papers

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

The invention provides anti-VISTA antibody drug conjugates which may be used for targeted delivery of anti-inflammatory agents such as steroids to immune cells, e.g., myeloid cells. The invention also provides methods of using anti-VISTA antibody drug conjugates in the treatment of inflammatory and/or autoimmune conditions and/or for alleviating the toxicity of anti-inflammatory agents such as steroids.

PYRAZOLE AMIDE DERIVATIVE

The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

PROCESS FOR PRODUCTION OF BICYCLOY2.2.2¨OCTYLAMINE DERIVATIVE

The present invention herein provides a process for production or a bicyclo[2.2.2]octylamine derivative which may be used as an intermediate for preparation of medical and pharmaceutical products. The process is quite efficient and can produce the derivative in a large-scale while using mild reaction conditions. The process for producing a bicyclo[2.2.2]octylamine derivative comprises the steps of subjecting, to ring-formation, a compound represented by the following general formula (1): [wherein R1 represents an alkyl group having 1 to 6 carbon atoms, which may have a substituent; an arylmethyl group which may have a substituent; or an arylethyl group which may have a substituent], and a compound represented by the following general formula (2): ????????R2-NH2?????(2) [wherein R2 represents an alkyl group having 1 to 6 carbon atoms, which may have a substituent; an aralkyl group which may have a substituent; a hydroxyl group; an alkyloxy group having 1 to 6 carbon atoms, which may have a substituent; or an aralkyloxy group which may have a substituent], and then reducing the resulting product.

BICYCLOESTER DERIVATIVE

SUMMARY Novel bicycloester derivatives and pharmaceutically acceptable salts thereof have high DPP-IV inhibitory activity. SOLVING MEANS The novel bicycloester derivatives are represented by the general formula (1): Pharmaceutically acceptable salts there